A Single Dose, Open-Label, Randomized Two-Period Crossover Study in Healthy Young Subjects to Assess the Absolute Bioavailability of Tasimelteon (HETLIOZ)
Latest Information Update: 24 Jul 2016
At a glance
- Drugs Tasimelteon (Primary) ; Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Pharmacokinetics
- Sponsors Vanda Pharmaceuticals
Most Recent Events
- 28 Jul 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2014 New trial record